Asian Pacific journal of allergy and immunology最新文献

{"title":"Cost-effectiveness analysis of corticosteroid nasal sprays for allergic rhinitis in Japan.","authors":"Naoto Nakagawa, Masami Kashiwabara, Kei Egawa","doi":"10.12932/AP-250625-2105","DOIUrl":"10.12932/AP-250625-2105","url":null,"abstract":"<p><strong>Background: </strong>Inflammation of the nasal lining, resulting in rhinorrhea and sneezing, leads to productivity losses.</p><p><strong>Objective: </strong>We aimed to clarify which corticosteroid nasal spray, dexamethasone cipecilate, fluticasone furoate, fluticasone propionate, or mometasone furoate hydrate, is more cost-effective in treating allergic rhinitis in Japan from the perspective of healthcare payers.</p><p><strong>Methods: </strong>A decision tree was generated using data on transition probabilities of effectiveness and side effects retrieved from post-marketing surveillance data. Direct medical costs were sourced from Medical Fee Index 2022. The drug prices were determined using the Drug Price Index 2021. Utilities were determined using the EQ-5D-5L scale. Deterministic and probabilistic sensitivity analyses were conducted to examine the robustness of the results. Prescription data for the fiscal year 2020 were also examined.</p><p><strong>Results: </strong>The incremental cost of mometasone furoate hydrate, dexamethasone cipecilate, and fluticasone furoate compared with that of fluticasone propionate was 200 JPY (1.99 USD), 440 JPY (4.37 USD), and 760 JPY (7.54 USD), respectively. The incremental effectiveness of mometasone furoate hydrate, dexamethasone cipecilate, and fluticasone furoate compared with that of fluticasone propionate was -0.0004, -0.0004, and -0.0002, respectively. Thus, mometasone furoate hydrate, dexamethasone cipecilate, and fluticasone furoate were dominated by fluticasone propionate. The sensitivity analyses showed that the result was robust. Prescription data showed that fluticasone furoate was prescribed most often, followed by mometasone furoate hydrate.</p><p><strong>Conclusions: </strong>Fluticasone propionate is the most cost-effective agent. As it was not often prescribed in the fiscal year 2020, physicians should understand our results to sustain the reduction of healthcare expenditures.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"436-444"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145278770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence rate and risk factors of recurrent anaphylaxis: A ten-year retrospective cohort study.","authors":"Suwannee Uthaisangsook, Nadda Padsee, Sagoontee Inkate","doi":"10.12932/AP-130325-2047","DOIUrl":"10.12932/AP-130325-2047","url":null,"abstract":"<p><strong>Background: </strong>Few studies have investigated the risk factors for recurrent anaphylaxis. Identifying these factors may help patients implement preventive measures.</p><p><strong>Objective: </strong>To determine the rate and risk factors for recurrent anaphylaxis, assess the time to recurrence, and compare the characteristics, triggers, and clinical manifestations between recurrent and non-recurrent cases.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted at Naresuan University Hospital from March 2011 to February 2021, using medical records of patients with ICD-10-confirmed anaphylaxis. Risk factors for recurrence were analyzed using Cox proportional hazards regression model.</p><p><strong>Results: </strong>A total of 439 anaphylactic episodes were identified in 381 patients (49 children, 332 adults). Of these, 42 patients (11.2%) experienced 58 recurrent episodes (7/49 [14.3%] children, 35/332 [10.6%] adults). Food and medications were the most and second most common triggers. The median time to recurrence was 9.9 months (IQR: 3.1-18.8), while the median follow-up duration for non-recurrent cases was 41.8 months (IQR: 23.8-61.8). The recurrent anaphylaxis rate was 4.1 events per 100 person-years. Statistically significant risk factors included a history of food, a history of insect, a history of drug allergies, chest discomfort, and severe anaphylaxis (HR [95%CI]: 3.31 [1.50-7.29], p = 0.003; 4.96 [1.47-16.82], p = 0.010; 5.87 [2.64-13.07], p < 0.001; 2.43 [1.19-4.99], p = 0.015; and 2.29 [1.07-4.88], p = 0.033, respectively). Conversely, palpitations were associated with a lower risk of recurrence (HR 0.11 [0.01-0.86], p = 0.036).</p><p><strong>Conclusions: </strong>Identifying risk factors in anaphylaxis patients enhances medical care and aids in preventing recurrence.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"445-455"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between meteorological variability and pollen sensitization over the past 10 years.","authors":"Fatma Arzu Akkuş, Fatih Çölkesen, Mehmet Emin Gerek, Tuğba Önalan, Recep Evcen, Filiz Sadi Aykan, Mehmet Kilinç, Şevket Arslan","doi":"10.12932/AP-240325-2054","DOIUrl":"10.12932/AP-240325-2054","url":null,"abstract":"<p><strong>Background: </strong>Meteorological changes can influence the type and concentration of allergenic pollen in the atmosphere.</p><p><strong>Objective: </strong>This study aimed to investigate the relationship between the diversity of pollen sensitivity based on skin prick test (SPT) reactions and meteorological changes over the past 10 years in Konya, Türkiye.</p><p><strong>Methods: </strong>A total of 23,111 patients who underwent skin prick testing (SPT) between January 2015 and December 2024 were included in the study. Meteorological data, including temperature, sunlight exposure, relative humidity, rainfall, and wind speed, were obtained from the 8th Regional Directorate of Meteorology.</p><p><strong>Results: </strong>Our analysis revealed significant relationships between meteorological parameters and pollen sensitivity. Sunlight duration was positively correlated with sensitivity to tree pollen (r = 0.608, p < 0.001). Wind speed was positively correlated with sensitivity to tree pollen (r = 0.433, p = 0.002) but negatively correlated with sensitivity to Chenopodium (r = -0.353, p = 0.013). Humidity was positively correlated with sensitivity to weed and grass pollen (r = 0.367, p = 0.022; r = 0.305, p = 0.033) and negatively correlated with sensitivity to tree pollen (r = -0.605, p < 0.001). Temperature was positively correlated with sensitivity to Artemisia vulgaris (r = 0.317, p = 0.034) and negatively correlated with sensitivity to weed pollen (r = -0.734, p < 0.001). Rainfall was negatively correlated with sensitivity to grass pollen (r = -0.296, p = 0.039), tree pollen (r = -0.850, p < 0.001), and Chenopodium (r = -0.408, p = 0.004).</p><p><strong>Conclusions: </strong>Our results revealed intricate interactions between pollen sensitivity and meteorological parameters. Notably, rainfall consistently exhibited a negative correlation with specific pollen types, suggesting a potential mitigating effect on pollen-related sensitization. These findings underscore the importance of considering meteorological variability in the management and prediction of allergic diseases.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"456-463"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145278897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of pre-existing immunity on humoral and cellular responses to CoronaVac in SARS-CoV-2 variants: A focus on common human Coronaviruses.","authors":"Nawamin Pinpathomrat, Bunya Seeyankem, Ratchanon Sophonmanee, Jomkwan Ongarj, Smonrapat Surasombatpattana","doi":"10.12932/AP-201124-1979","DOIUrl":"10.12932/AP-201124-1979","url":null,"abstract":"<p><strong>Background: </strong>The global COVID-19 pandemic, caused by SARS-CoV-2, has highlighted the importance of understanding immune responses elicited by vaccines.</p><p><strong>Objective: </strong>This study evaluated antibody and T cell responses to the inactivated CoronaVac vaccine, as well as the role of pre-existing immunity to common human coronaviruses (HCoVs) in shaping vaccine-induced immunity.</p><p><strong>Methods: </strong>We enrolled 64 participants (17 males and 47 females) and measured IgG levels against HCoVs before and after vaccination. T cell responses were analysed by stimulating peripheral blood mononuclear cells (PBMCs) with wild-type, Delta, and Omicron spike peptides.</p><p><strong>Results: </strong>We found pre-existing antibodies against HCoV-229E, HCoV-HKU1, HCoV-NL63, and HCoV-OC43 were present before vaccination. Notably, a positive correlation was observed between pre-existing antibodies to HCoV-229E and HCoV-HKU1 and anti-RBD IgG levels post-vaccination. Pre-existing CD4+ T cell responses were observed for the wild-type strain before vaccination, with a significant reduction in IFN-γ secretion after Delta re-stimulation and partial restoration after Omicron re-stimulation. IL-4 production by CD4+ T cells was significantly reduced upon re-stimulation with Delta and Omicron compared to wild-type. CD8+ T cells again showed a reduction of IL-4 production after Delta re-stimulation compared to the original strain.</p><p><strong>Conclusions: </strong>This work demonstrate that CoronaVac induces robust humoral and cellular immune responses, though variant-specific responses vary. Pre-existing immunity to certain HCoVs may influence vaccine-induced antibody responses, underscoring the importance of monitoring immunity to emerging SARS-CoV-2 variants and informing future vaccine design.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"495-503"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type 2-interferon imbalance in allergic barrier disease: An asthma-centered, cross-disease perspective.","authors":"Shenghong Rao, Shumei Li, Haoyue Shen, Tengchuan Jin","doi":"10.12932/AP-150526-2295","DOIUrl":"https://doi.org/10.12932/AP-150526-2295","url":null,"abstract":"<p><p>Allergic diseases are typically regarded as type 2 inflammatory disorders driven by interleukin-4, interleukin-5, and interleukin-13, which mediate immunoglobulin E class switching, eosinophilic inflammation, mucus hypersecretion, pruritus, tissue remodeling, and epithelial barrier dysfunction. However, type 2 cytokine activity alone does not fully account for variations in exacerbation risk, susceptibility to infections, comorbidities, or responses to biologic therapy. This narrative review proposes an asthma-centered type 2-interferon imbalance framework and discusses its cautious, disease-specific extension to atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and food allergy. The model emphasizes that, particularly in asthma, allergic barrier inflammation arises and persists in injured tissues where excessive type 2 inflammation may coexist with impaired interferon-mediated host defense. Evidence is strongest in asthma, where deficiencies in type I and type III interferon responses are linked to rhinovirus susceptibility, delayed viral clearance, and recurrent exacerbations. In other allergic diseases, interferon dysfunction appears more variable, reflecting differences in tissue context, disease stage, and environmental exposure. In asthma, and potentially in selected allergic barrier diseases, persistent inflammation may result from a cycle of epithelial injury, alarmin release, cytokine amplification, impaired antiviral defense, ongoing exposure, and incomplete tissue repair. These mechanisms provide a rationale for tiered intervention, including blockade of upstream epithelial alarmins, inhibition of downstream type 2 effector pathways, and selected investigational approaches aimed at restoring mucosal host defense.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":"44 3","pages":"427-435"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149007774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergic contact dermatitis from a clonidine transdermal patch used to treat tic disorders: First pediatric case report and literature review.","authors":"Yingyang Xu, Yi Lu, Kai Guan","doi":"10.12932/AP-161125-2178","DOIUrl":"10.12932/AP-161125-2178","url":null,"abstract":"<p><strong>Background: </strong>Recently, clonidine has been increasingly utilized for the treatment of tic disorders in children rather than for hypertension in adults. The transdermal patch is a common route of administration. Allergic contact dermatitis caused by clonidine transdermal patch was reported in adults with hypertension but never in children with tic disorder.</p><p><strong>Objective: </strong>We report on the first pediatric case developed allergic contact dermatitis within one to two weeks after using clonidine transdermal patch.</p><p><strong>Methods: </strong>Patch test with clonidine and Chinese baseline series including adhesive components (ethyl acrylate, methyl methacrylate, and 2-hydroxyethyl methacrylate) from the adhesive layer of the transdermal patch were performed.</p><p><strong>Results: </strong>We report the first pediatric case with allergic contact dermatitis due to clonidine transdermal patch confirmed by patch test. She presented with pruritic erythema, blistering, and rupture at the patch site, matching its size and shape. Patch test with clonidine hydrochloride elicited positive reactions (++ to +++), while tests for specific components from the adhesive layer, including ethyl acrylate, methyl methacrylate, and 2-hydroxyethyl methacrylate, were negative, thereby identifying clonidine as the primary allergen.</p><p><strong>Conclusions: </strong>This case highlights that although clonidine itself has weak sensitizing potential, the transdermal therapeutic system may increase the risk of clonidine-induced sensitization and make it become a potential trigger for allergic contact dermatitis in clonidine transdermal patch users.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"490-494"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148142639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of biologics in children and adolescents with eosinophilic asthma: A systematic review and meta-Analysis.","authors":"Yulin Geng, Junmei Xu","doi":"10.12932/AP-151025-2164","DOIUrl":"10.12932/AP-151025-2164","url":null,"abstract":"<p><strong>Background: </strong>Eosinophilic asthma is a severe phenotype in pediatrics, often refractory to conventional therapy. Biologic agents targeting Type 2 inflammatory pathway are increasingly used in children and adolescents.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of omalizumab, mepolizumab, benralizumab, and dupilumab in pediatric eosinophilic asthma.</p><p><strong>Methods: </strong>We systematically searched eight databases to March 31, 2025 (PROSPERO: CRD420251017602). Eligible studies were randomized controlled or controlled observational trials in patients 1≤8 years. Outcomes included lung function, asthma control, quality of life (QoL), and adverse events (AEs).</p><p><strong>Results: </strong>Twenty-two studies (n = 2,468) were included. Biologics significantly improved predicted FEV1 (SMD = 0.97, 95%CI: 0.38-1.57), asthma control also improved (SMD = 2.84, 95%CI: 1.40-4.28), as did quality of life (SMD = 1.72, 95%CI: 0.39-3.05). Overall AEs were more frequent (OR 1.48, 95%CI 1.22-1.81), but serious AEs were rare and not increased. Evidence was strongest for omalizumab; data for other biologics remain limited.</p><p><strong>Conclusions: </strong>Biologic therapies are associated with improvements in clinical outcomes in children and adolescents with eosinophilic asthma, with an increased incidence of predominantly mild adverse events. However, the current evidence is largely driven by studies of omalizumab, and data for other biologics remain limited in pediatric populations. Further long-term and comparative studies are warranted to better define the efficacy and safety profiles of individual biologic agents.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"482-489"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147462687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of subcutaneous and sublingual allergen immunotherapy on immune responses in children with bronchial asthma.","authors":"Jinfeng Wei, Cuiying Ye, Xiangying Wang, Li Zhang, Suling Wu, Xuefeng Jin","doi":"10.12932/AP-050625-2089","DOIUrl":"10.12932/AP-050625-2089","url":null,"abstract":"<p><strong>Background: </strong>Allergic asthma in children significantly impacts quality of life, and immunotherapy, including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), has emerged as an effective treatment. However, their comparative immunological mechanisms remain unclear.</p><p><strong>Objective: </strong>This study aimed to compare the effects of SCIT and SLIT on immune response in children with allergic asthma and to explore their underlying immunological mechanisms.</p><p><strong>Methods: </strong>A total of 86 children aged 5-12 years with allergic asthma who visited Hangzhou Children's Hospital were prospectively enrolled and randomly assigned to three groups: inhaled corticosteroids (ICS) group (n = 30), SCIT group (n = 30), and SLIT group (n = 26). Clinical and immunological parameters-including Childhood Asthma Control Test (C-ACT) scores, forced expiratory volume in the first second percentage (FEV1%), Th17, Treg cells, and serum levels of IL-17, IL-9, IL-10-were assessed before treatment and after one year.</p><p><strong>Results: </strong>After treatment, all three groups showed significant improvements in C-ACT scores and FEV1% compared to baseline (all p < 0.05). The SCIT and SLIT groups demonstrated greater improvements than the ICS group (all p < 0.05), with no significant differences between the SCIT and SLIT groups (p > 0.05). In terms of immune markers, significant differences were observed in all parameters before and after treatment in the SCIT and SLIT groups (all p < 0.05), while Treg levels in the ICS group remained unchanged (p > 0.05). No statistically significant differences in immune markers were found among the three groups post-treatment (all p >0.05).</p><p><strong>Conclusions: </strong>Both SCIT and SLIT, when combined with ICS, offer superior efficacy compared to ICS monotherapy. The comparable immunological changes observed in SCIT and SLIT suggest a shared mechanism of immune tolerance, potentially mediated through Treg cell induction.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"475-481"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147462661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Amb t 18 as a novel allergen from Ambrosia trifida pollen.","authors":"Yi-Fei Xu, Ke Li, Li-Xiang Zhu, Ya-Li Cheng, Yong-Shi Yang, Zhi-Qiang Xu, Jin-Lyu Sun, Ji-Fu Wei","doi":"10.12932/AP-120425-2065","DOIUrl":"10.12932/AP-120425-2065","url":null,"abstract":"<p><strong>Background: </strong>Ambrosia (ragweed) pollen is a major allergenic source, but Ambrosia trifida allergens remain understudied. Triosephosphate isomerase, a conserved pan-allergen in plants, has not been reported in weed pollen.</p><p><strong>Objective: </strong>To identify and characterize the novel allergen (Amb t 18) and evaluated its clinical relevance.</p><p><strong>Methods: </strong>Amb t 18 cDNA was cloned and expressed in E. coli. Natural (nAmb t 18) and recombinant (rAmb t 18) proteins were purified for structural analyses (CD spectra) and IgE-reactivity testing (ELISA/basophil activation). Cross-reactivity with homologs Pla a 7 and Tri a 31 was assessed through inhibition ELISA. Structural analyses included 3D modeling, sequence alignment, and phylogenetics.</p><p><strong>Results: </strong>Natural and recombinant Amb t 18 exhibited similar CD spectra. Amb t 18 reacted with 35.1% (13/37) of serum samples, inhibited 17.56% of IgE-binding to pollen extracts, and activated basophils. In some sera, its IgE-binding activity exceeded that of ragweed pollen extracts. It shared 82% sequence identity with Pla a 7 and Tri a 31, grouped together in the phylogenetic tree. The recombinant Amb t 18 reacted with Pla a 7 or Tri a 31 IgE-positive sera from Platanus acerifolia or Triticum aestivum-allergic patients, rAmb t 18, rPla a 7, and rTri a 31 inhibited IgE binding to rAmb t 18 by 76.70%, 5.80%, and 21.94%, respectively.</p><p><strong>Conclusions: </strong>Amb t 18 was identified as a novel Ambrosia trifida pollen allergen, the first of its type in ragweed pollen. These findings may aid in developing new diagnostic and therapeutic approaches for ragweed allergy.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"464-474"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145278812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced performances of the short-PCR coupled lateral flow assay in the detection of Candida albicans in clinical blood samples.","authors":"Oranee Srichaiyapol, Bhanubong Saiboonjan, Sawinee Ngernpimai, Chonphaksorn Ponsue, Nutcha Sa-Ingthong, Patsara Thongmee, Lumyai Wonglakorn, Chutipapa Sukkasem, Rinjong Promson Kendal, Jureerut Daduang, Ratree Tavichakorntrakool, Arpasiri Srisrattakarn, Aroonwadee Chanawong, Molin Wongwattanakul, Aroonlug Lulitanond, Patcharaporn Tippayawat","doi":"10.12932/AP-190125-2018","DOIUrl":"10.12932/AP-190125-2018","url":null,"abstract":"<p><strong>Background: </strong>Candida albicans remains the most common fungal pathogen among the species, causing candidemia. Thus, early diagnosis is indispensable in patients with severe underlying infections.</p><p><strong>Objective: </strong>To develop a short-polymerase chain reaction (short-PCR) coupled with lateral flow strip (LFS) assay for the detection of C. albicans in clinical blood samples.</p><p><strong>Methods: </strong>A short-PCR-LFS was enhanced to detect clinical isolates and clinical blood samples. The ITS2 gene of C. albicans was amplified using the modified primers-probes to produce highly specific, dual-labeled amplicons. The sensitivity and specificity of the test system were evaluated using C. albicans, Candida spp. other than C. albicans and other microbial DNAs. The test system was validated by 44 clinical isolates and 51 clinical blood samples.</p><p><strong>Results: </strong>The short-PCR-LFS revealed a high specificity for C. albicans with no cross-reactivity and a limit of detection (LOD) of 0.1 ng per 2 mL of blood and 2 CFU/mL using a direct colony as a template. The result was consistent with the validation by short-PCR agarose gel electrophoresis (AGE). The short-PCR-LFS assay showed all positives with all C. albicans relevant samples and exhibited negative for other microbial relevance samples.</p><p><strong>Conclusions: </strong>The entire process of this system provides visual detection results less than 1 h with high sensitivity, high specificity, DNA extraction-free method, and little dependence on instruments. Thus, it can be considered as a promising method for professional use to early detect and identify clinical relevance samples of C. albicans.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"504-518"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}